Amanda Bader
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amanda Bader has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Heather Wachtel
Department of Surgery, University of Pennsylvania Health System, Philadelphia, Pennsylvania
3 shared publications - Jasmine Hwang
Department of Surgery University of Pennsylvania Philadelphia Pennsylvania USA
3 shared publications Douglas Fraker
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
2 shared publications- Jesse E. Passman
Department of Surgery University of Pennsylvania Philadelphia Pennsylvania USA
2 shared publications - Maria S. Altieri
University of Pennsylvania, Philadelphia, PA, USA
2 shared publications - Caitlin B. Finn
Department of Surgery, Center for Surgery and Health Economics, University of Pennsylvania, Pennsylvania
1 shared publication
Latest Publications
- 14 November 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1658-1669
Readmission and Cost of Parathyroidectomy By Admission Status in Secondary Hyperparathyroidism
Key Points: Among patients with kidney failure treated with dialysis, 37% underwent parathyroidectomy in the outpatient setting. Significant differences exist between patients selected for inpatient versus outpatient parathyroidectomy. Risk-adjusted readmission rates are similar after inpatient or outpatient parathyroidectomy for secondary hyperparathyroidism. Background: Outpatient parathyroidectomy for secondary hyperparathyroidism of kidney disease is increasing. Reduced length of stay is often associated with higher rates of readmission. The safety of outpatient parathyroidectomy in this population must be evaluated given the morbidity and higher risk of post-parathyroidectomy hungry bone syndrome associated with kidney failure. In this study, we compare parathyroidectomy outcomes and costs by admission status in dialysis-dependent patients with secondary hyperparathyroidism. Methods: Adult patients on dialysis who underwent elective parathyroidectomy for secondary hyperparathyroidism were identified in the Healthcare Cost and Utilization Project State Inpatient and State Ambulatory Surgery Databases from five geographically diverse states (2013–2019). Patients were classified by admission status: inpatient and outpatient (overnight or same-day). The primary outcome was 30-day readmission. Secondary outcomes were parathyroidectomy-related complications and cost. Outcomes were compared by admission status using chi-squared tests and costs using median quantile regression. Balancing weights were used for adjustment. Forward selection with logistic regression was used to identify factors associated with readmission among outpatients. Results: Among 1267 study participants, 63% were inpatients. Among outpatients, 40% underwent overnight stay and 42% underwent same-day discharge. Inpatients were more likely to be younger, Black race, have nonprivate insurance, and increased comorbidities than outpatients ( P < 0.05). Overall readmission rate was 19%. Readmission was higher among inpatients (Inpatient: 22% versus Outpatient: 15%; P = 0.002). After balancing weights, adjusted 30-day readmission rate was similar between inpatients and outpatients (14% versus 15%; P = 0.79). Readmission was similar between overnight stay and same-day discharge (Unadjusted: 12% versus 15%; P = 0.47. Adjusted: 15% versus 15%; P = 0.97). Outpatients with parathyroid autotransplantation, anxiety disorder, autoimmune conditions, congestive heart failure, and moderate/severe liver failure had significantly increased odds of readmission after parathyroidectomy. Adjusted median costs varied significantly (Adjusted Inpatient: $9615 [Interquartile range (IQR), $6463–12,963] versus Outpatient: $6357 [IQR, $4966–8153]; P < 0.001; Adjusted Overnight: $6453 [IQR, $5551–7850] versus Same-day: $5526 [IQR, $4346–7187]; P < 0.001). Conclusions: Select patients with secondary hyperparathyroidism may undergo outpatient parathyroidectomy safely with reduced costs.
- 14 November 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (12) , 1658-1669
Readmission and Cost of Parathyroidectomy By Admission Status in Secondary Hyperparathyroidism
Key Points: Among patients with kidney failure treated with dialysis, 37% underwent parathyroidectomy in the outpatient setting. Significant differences exist between patients selected for inpatient versus outpatient parathyroidectomy. Risk-adjusted readmission rates are similar after inpatient or outpatient parathyroidectomy for secondary hyperparathyroidism. Background: Outpatient parathyroidectomy for secondary hyperparathyroidism of kidney disease is increasing. Reduced length of stay is often associated with higher rates of readmission. The safety of outpatient parathyroidectomy in this population must be evaluated given the morbidity and higher risk of post-parathyroidectomy hungry bone syndrome associated with kidney failure. In this study, we compare parathyroidectomy outcomes and costs by admission status in dialysis-dependent patients with secondary hyperparathyroidism. Methods: Adult patients on dialysis who underwent elective parathyroidectomy for secondary hyperparathyroidism were identified in the Healthcare Cost and Utilization Project State Inpatient and State Ambulatory Surgery Databases from five geographically diverse states (2013–2019). Patients were classified by admission status: inpatient and outpatient (overnight or same-day). The primary outcome was 30-day readmission. Secondary outcomes were parathyroidectomy-related complications and cost. Outcomes were compared by admission status using chi-squared tests and costs using median quantile regression. Balancing weights were used for adjustment. Forward selection with logistic regression was used to identify factors associated with readmission among outpatients. Results: Among 1267 study participants, 63% were inpatients. Among outpatients, 40% underwent overnight stay and 42% underwent same-day discharge. Inpatients were more likely to be younger, Black race, have nonprivate insurance, and increased comorbidities than outpatients ( P < 0.05). Overall readmission rate was 19%. Readmission was higher among inpatients (Inpatient: 22% versus Outpatient: 15%; P = 0.002). After balancing weights, adjusted 30-day readmission rate was similar between inpatients and outpatients (14% versus 15%; P = 0.79). Readmission was similar between overnight stay and same-day discharge (Unadjusted: 12% versus 15%; P = 0.47. Adjusted: 15% versus 15%; P = 0.97). Outpatients with parathyroid autotransplantation, anxiety disorder, autoimmune conditions, congestive heart failure, and moderate/severe liver failure had significantly increased odds of readmission after parathyroidectomy. Adjusted median costs varied significantly (Adjusted Inpatient: $9615 [Interquartile range (IQR), $6463–12,963] versus Outpatient: $6357 [IQR, $4966–8153]; P < 0.001; Adjusted Overnight: $6453 [IQR, $5551–7850] versus Same-day: $5526 [IQR, $4346–7187]; P < 0.001). Conclusions: Select patients with secondary hyperparathyroidism may undergo outpatient parathyroidectomy safely with reduced costs.
- Open Access
- 2 September 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (9) , e2530787
Bariatric Surgery and Incident Development of Obesity-Related Comorbidities
Importance: As obesity rates rise in the US, managing associated metabolic comorbidities presents a growing burden to the health care system. While bariatric surgery has shown promise in mitigating established metabolic conditions, no large studies have quantified the risk of developing major obesity-related comorbidities after bariatric surgery.Objective: To identify common metabolic phenotypes for patients eligible for bariatric surgery and to estimate crude and adjusted incidence rates of additional metabolic comorbidities associated with bariatric surgery compared with weight management program (WMP) alone.Design, Setting, and Participants: This retrospective, multicenter cohort study used data from the Veterans Health Administration (VHA) Corporate Data Warehouse, which incorporates data from 128 VHA centers. Participants were adults 18 years or older with a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 30 or higher and at least 1 of 5 metabolic comorbidities or with a BMI of 35 or higher who underwent bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) or enrolled in the WMP (called MOVE!) between January 1, 2008, and December 31, 2023. Patients with all 5 comorbidities at baseline or missing key data were excluded.Exposure: Bariatric surgery vs WMP.Main Outcome and Measures: Incident diagnosis of any of 5 metabolic comorbidities: type 2 diabetes (T2D), hypertension, hyperlipidemia, obstructive sleep apnea (OSA), and metabolic dysfunction–associated steatotic liver disease (MASLD).Results: Among 269 470 veterans, 263 657 were enrolled in the WMP and 5813 underwent bariatric surgery. Patients included 232 196 males (87.1%) and had a median (IQR) age of 57 (47-64) years. Median (IQR) follow-up time was 112.9 (79.5-145.4) months. At 5 years, incidence rates per 1000 person-years were 8.89 for hypertension, 9.67 for hyperlipidemia, 4.29 for T2D, 3.99 for OSA, and 2.44 for MASLD in the WMP group. For the bariatric surgery group, incidence rates per 1000 person-years were 3.35 for hypertension, 4.85 for hyperlipidemia, 1.06 for T2D, 3.43 for OSA, and 2.01 for MASLD. Bariatric surgery was associated with a statistically significant lower risk of incident T2D (79.2% lower; hazard ratio [HR], 0.21 [95% CI, 0.18-0.26]), hypertension (58.8% lower; HR, 0.41 [95% CI, 0.33-0.51]), hyperlipidemia (50.5% lower; HR, 0.49 [95% CI, 0.42-0.58]), OSA (56.9% lower; HR, 0.43 [95% CI, 0.35-0.52]), and MASLD (40.4% lower; HR, 0.60 [95% CI, 0.49-0.73]) compared with the WMP. Results were consistent in a subgroup analysis of only female veterans.Conclusions and Relevance: In this cohort study, bariatric surgery was associated with a significantly lower risk of developing major metabolic comorbidities compared with the medical WMP. This finding supports the relevance of bariatric surgery as a durable approach for obesity-related risk mitigation.
- 2 September 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (9) , e2530787
Open AccessBariatric Surgery and Incident Development of Obesity-Related Comorbidities
Importance: As obesity rates rise in the US, managing associated metabolic comorbidities presents a growing burden to the health care system. While bariatric surgery has shown promise in mitigating established metabolic conditions, no large studies have quantified the risk of developing major obesity-related comorbidities after bariatric surgery.Objective: To identify common metabolic phenotypes for patients eligible for bariatric surgery and to estimate crude and adjusted incidence rates of additional metabolic comorbidities associated with bariatric surgery compared with weight management program (WMP) alone.Design, Setting, and Participants: This retrospective, multicenter cohort study used data from the Veterans Health Administration (VHA) Corporate Data Warehouse, which incorporates data from 128 VHA centers. Participants were adults 18 years or older with a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 30 or higher and at least 1 of 5 metabolic comorbidities or with a BMI of 35 or higher who underwent bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) or enrolled in the WMP (called MOVE!) between January 1, 2008, and December 31, 2023. Patients with all 5 comorbidities at baseline or missing key data were excluded.Exposure: Bariatric surgery vs WMP.Main Outcome and Measures: Incident diagnosis of any of 5 metabolic comorbidities: type 2 diabetes (T2D), hypertension, hyperlipidemia, obstructive sleep apnea (OSA), and metabolic dysfunction–associated steatotic liver disease (MASLD).Results: Among 269 470 veterans, 263 657 were enrolled in the WMP and 5813 underwent bariatric surgery. Patients included 232 196 males (87.1%) and had a median (IQR) age of 57 (47-64) years. Median (IQR) follow-up time was 112.9 (79.5-145.4) months. At 5 years, incidence rates per 1000 person-years were 8.89 for hypertension, 9.67 for hyperlipidemia, 4.29 for T2D, 3.99 for OSA, and 2.44 for MASLD in the WMP group. For the bariatric surgery group, incidence rates per 1000 person-years were 3.35 for hypertension, 4.85 for hyperlipidemia, 1.06 for T2D, 3.43 for OSA, and 2.01 for MASLD. Bariatric surgery was associated with a statistically significant lower risk of incident T2D (79.2% lower; hazard ratio [HR], 0.21 [95% CI, 0.18-0.26]), hypertension (58.8% lower; HR, 0.41 [95% CI, 0.33-0.51]), hyperlipidemia (50.5% lower; HR, 0.49 [95% CI, 0.42-0.58]), OSA (56.9% lower; HR, 0.43 [95% CI, 0.35-0.52]), and MASLD (40.4% lower; HR, 0.60 [95% CI, 0.49-0.73]) compared with the WMP. Results were consistent in a subgroup analysis of only female veterans.Conclusions and Relevance: In this cohort study, bariatric surgery was associated with a significantly lower risk of developing major metabolic comorbidities compared with the medical WMP. This finding supports the relevance of bariatric surgery as a durable approach for obesity-related risk mitigation.
- Open Access
- 10 January 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 39 (2) , 1318-1322
Gender gap in surgical societies awards
Introduction: Despite remarkable progress, gender inequality in medicine remains a significant issue. This disparity extends beyond clinical practices and educational programs; it is also evident in the recognition and awards received by surgeons. Underrepresentation of women in Surgical Society awards is a multi-layered issue that needs a holistic approach since these awards are used to hire, promote, and advance surgeons. Methods and Procedures: A retrospective observational study was performed between 1936 and 2023 on all recipients of awards from 22 surgical societies. The study examines the relationship between recipient gender and award year. Medians, and interquartile ranges (IQRs) were used for continuous data, and frequencies and percentages were used for categorical data. Chi-square and Wilcoxon rank sum tests were used to compare female and male recipients. Multiple logistic regression was used to estimate the probability that a female will receive an award. Results: A total of 2588 awards were given out between 1936 and 2023. Among the 2588 awards, 2024 went to male surgeons, and 564 to female surgeons. Since 1936, there have been 0–25 women awarded annually, with a proportion of female awardees between 0 and 0.5. Since 1936, the proportion of women awardees has increased significantly (p < 0.01). Since 2006, female award winners have increased by 0.7% (95% CI 0.007–0.008, p = 0.001) when controlling for surgical societies. A woman’s odds of receiving an award from a surgical society have increased by only 3% per year since 2006 (OR 1.03, 95% CI 1.01–1.07, p = 0.004). Accordingly, female surgeon awards grew from 0.22 in 2006 to 0.35 in 2023. Conclusion: Female surgeons’ continuous underrepresentation in Surgical Society awards is a crucial issue. The selection process of surgical societies needs to be more intentional as female recipients have steadily increased in recent years. Closing this gender gap is not only a matter of fairness but also imperative for the field’s progress.
- 10 January 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 39 (2) , 1318-1322
Open AccessGender gap in surgical societies awards
Introduction: Despite remarkable progress, gender inequality in medicine remains a significant issue. This disparity extends beyond clinical practices and educational programs; it is also evident in the recognition and awards received by surgeons. Underrepresentation of women in Surgical Society awards is a multi-layered issue that needs a holistic approach since these awards are used to hire, promote, and advance surgeons. Methods and Procedures: A retrospective observational study was performed between 1936 and 2023 on all recipients of awards from 22 surgical societies. The study examines the relationship between recipient gender and award year. Medians, and interquartile ranges (IQRs) were used for continuous data, and frequencies and percentages were used for categorical data. Chi-square and Wilcoxon rank sum tests were used to compare female and male recipients. Multiple logistic regression was used to estimate the probability that a female will receive an award. Results: A total of 2588 awards were given out between 1936 and 2023. Among the 2588 awards, 2024 went to male surgeons, and 564 to female surgeons. Since 1936, there have been 0–25 women awarded annually, with a proportion of female awardees between 0 and 0.5. Since 1936, the proportion of women awardees has increased significantly (p < 0.01). Since 2006, female award winners have increased by 0.7% (95% CI 0.007–0.008, p = 0.001) when controlling for surgical societies. A woman’s odds of receiving an award from a surgical society have increased by only 3% per year since 2006 (OR 1.03, 95% CI 1.01–1.07, p = 0.004). Accordingly, female surgeon awards grew from 0.22 in 2006 to 0.35 in 2023. Conclusion: Female surgeons’ continuous underrepresentation in Surgical Society awards is a crucial issue. The selection process of surgical societies needs to be more intentional as female recipients have steadily increased in recent years. Closing this gender gap is not only a matter of fairness but also imperative for the field’s progress.
- 28 October 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 239, 116048
Demystifying delays: Factors associated with timely treatment of adrenocortical carcinoma
- 28 October 2024
- Published by Elsevier in The American Journal of Surgery
- Vol. 239, 116048
Demystifying delays: Factors associated with timely treatment of adrenocortical carcinoma